{"id":1004633,"date":"2026-09-19T19:34:01","date_gmt":"2026-09-19T23:34:01","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/clls-investors-have-opportunity-to-join-cellectis-s-a-fraud-investigation-with-sbs-law\/"},"modified":"2026-09-19T19:34:01","modified_gmt":"2026-09-19T23:34:01","slug":"clls-investors-have-opportunity-to-join-cellectis-s-a-fraud-investigation-with-sbs-law","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/clls-investors-have-opportunity-to-join-cellectis-s-a-fraud-investigation-with-sbs-law\/","title":{"rendered":"CLLS Investors Have Opportunity to Join Cellectis S.A. Fraud Investigation with SBS Law"},"content":{"rendered":"

<\/p>\n

CLLS Investors Have Opportunity to Join Cellectis S.A. Fraud Investigation with SBS Law<\/b><\/p>\n

LOS ANGELES–(BUSINESS WIRE<\/a>)–Schall, Brown & Schwartz<\/a> LLP (\u201cSBS\u201d), a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cellectis S.A. (\u201cCellectis\u201d or \u201cthe Company\u201d) (NASDAQ: CLLS<\/a>) for violations of the securities laws.<\/p>\n

INVESTIGATION DETAILS: <\/b>The investigation focuses on whether the Company issued false and\/or misleading statements and\/or failed to disclose information pertinent to investors. Cellectis announced on September 14, 2026, that it would prioritize in vivo gene editing therapies over CAR-T cell therapies. The Company also announced the discontinuation of development of certain CAR-T cell therapies. The Company\u2019s Chief Medical Officer stated, “Cellectis is not able finance [Eti-cel and Lasme-cel] given the time lines that we have and the limited cash resources that we have.” Based on this news, shares of Cellectis fell by almost 41% on the same day.<\/p>\n

\nIf you are a shareholder who suffered a loss, click here to participate<\/a>.<\/p>\n

\nWe also encourage you to contact Brian Schall or David Schwartz of Schall, Brown & Schwartz LLP, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm’s website at www.schallfirm.com<\/a>, or by email at david@schallfirm.com<\/a>.<\/p>\n

WHY SBS?<\/b> Schall, Brown & Schwartz LLP represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation. Bringing together the extensive experience and diverse skillsets of founding partners Brian Schall, Andrew Brown, and David Schwartz, SBS is dedicated to aggressively advocating for every investor.<\/p>\n

\nThis press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.<\/p>\n

\"\"<\/p>\n

View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20260919446999\/en\/<\/a><\/span><\/p>\n

\nSchall, Brown & Schwartz LLP
\n
Brian Schall, Esq.,
\n
Andrew Brown, Esq.,
\n
David Schwartz, Esq.,
\n
www.schallfirm.com
\n<\/a>
Office: 310-301-3335
\n
info@schallfirm.com<\/a><\/p>\n

KEYWORDS:<\/b> United States North America California<\/p>\n

INDUSTRY KEYWORDS:<\/b> Class Action Lawsuit Professional Services Legal<\/p>\n

MEDIA:<\/b><\/p>\n\n\n\n\n
Logo<\/b><\/font><\/td>\n<\/tr>\n
\"Logo\"<\/td>\n<\/tr>\n
<\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"

CLLS Investors Have Opportunity to Join Cellectis S.A. Fraud Investigation with SBS Law LOS ANGELES–(BUSINESS WIRE)–Schall, Brown & Schwartz LLP (\u201cSBS\u201d), a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cellectis S.A. (\u201cCellectis\u201d or \u201cthe Company\u201d) (NASDAQ: CLLS) for violations of the securities laws. INVESTIGATION DETAILS: The investigation focuses on whether the Company issued false and\/or misleading statements and\/or failed to disclose information pertinent to investors. Cellectis announced on September 14, 2026, that it would prioritize in vivo gene editing therapies over CAR-T cell therapies. The Company also announced the discontinuation of development of certain CAR-T cell therapies. The Company\u2019s Chief Medical Officer stated, “Cellectis is not able finance [Eti-cel and Lasme-cel] … <\/p>\n

Continue reading “CLLS Investors Have Opportunity to Join Cellectis S.A. Fraud Investigation with SBS Law”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-1004633","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nCLLS Investors Have Opportunity to Join Cellectis S.A. Fraud Investigation with SBS Law - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/clls-investors-have-opportunity-to-join-cellectis-s-a-fraud-investigation-with-sbs-law\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"CLLS Investors Have Opportunity to Join Cellectis S.A. Fraud Investigation with SBS Law - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"CLLS Investors Have Opportunity to Join Cellectis S.A. Fraud Investigation with SBS Law LOS ANGELES–(BUSINESS WIRE)–Schall, Brown & Schwartz LLP (\u201cSBS\u201d), a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cellectis S.A. (\u201cCellectis\u201d or \u201cthe Company\u201d) (NASDAQ: CLLS) for violations of the securities laws. INVESTIGATION DETAILS: The investigation focuses on whether the Company issued false and\/or misleading statements and\/or failed to disclose information pertinent to investors. Cellectis announced on September 14, 2026, that it would prioritize in vivo gene editing therapies over CAR-T cell therapies. The Company also announced the discontinuation of development of certain CAR-T cell therapies. The Company\u2019s Chief Medical Officer stated, “Cellectis is not able finance [Eti-cel and Lasme-cel] … Continue reading "CLLS Investors Have Opportunity to Join Cellectis S.A. Fraud Investigation with SBS Law"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/clls-investors-have-opportunity-to-join-cellectis-s-a-fraud-investigation-with-sbs-law\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-09-19T23:34:01+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20260919446999r1&sid=flmnd&distro=nx&lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/clls-investors-have-opportunity-to-join-cellectis-s-a-fraud-investigation-with-sbs-law\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/clls-investors-have-opportunity-to-join-cellectis-s-a-fraud-investigation-with-sbs-law\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"CLLS Investors Have Opportunity to Join Cellectis S.A. Fraud Investigation with SBS Law\",\"datePublished\":\"2026-09-19T23:34:01+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/clls-investors-have-opportunity-to-join-cellectis-s-a-fraud-investigation-with-sbs-law\\\/\"},\"wordCount\":357,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/clls-investors-have-opportunity-to-join-cellectis-s-a-fraud-investigation-with-sbs-law\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20260919446999r1&sid=flmnd&distro=nx&lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/clls-investors-have-opportunity-to-join-cellectis-s-a-fraud-investigation-with-sbs-law\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/clls-investors-have-opportunity-to-join-cellectis-s-a-fraud-investigation-with-sbs-law\\\/\",\"name\":\"CLLS Investors Have Opportunity to Join Cellectis S.A. Fraud Investigation with SBS Law - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/clls-investors-have-opportunity-to-join-cellectis-s-a-fraud-investigation-with-sbs-law\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/clls-investors-have-opportunity-to-join-cellectis-s-a-fraud-investigation-with-sbs-law\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20260919446999r1&sid=flmnd&distro=nx&lang=en\",\"datePublished\":\"2026-09-19T23:34:01+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/clls-investors-have-opportunity-to-join-cellectis-s-a-fraud-investigation-with-sbs-law\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/clls-investors-have-opportunity-to-join-cellectis-s-a-fraud-investigation-with-sbs-law\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/clls-investors-have-opportunity-to-join-cellectis-s-a-fraud-investigation-with-sbs-law\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20260919446999r1&sid=flmnd&distro=nx&lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20260919446999r1&sid=flmnd&distro=nx&lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/clls-investors-have-opportunity-to-join-cellectis-s-a-fraud-investigation-with-sbs-law\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"CLLS Investors Have Opportunity to Join Cellectis S.A. Fraud Investigation with SBS Law\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"CLLS Investors Have Opportunity to Join Cellectis S.A. Fraud Investigation with SBS Law - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/clls-investors-have-opportunity-to-join-cellectis-s-a-fraud-investigation-with-sbs-law\/","og_locale":"en_US","og_type":"article","og_title":"CLLS Investors Have Opportunity to Join Cellectis S.A. Fraud Investigation with SBS Law - Market Newsdesk","og_description":"CLLS Investors Have Opportunity to Join Cellectis S.A. Fraud Investigation with SBS Law LOS ANGELES–(BUSINESS WIRE)–Schall, Brown & Schwartz LLP (\u201cSBS\u201d), a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cellectis S.A. (\u201cCellectis\u201d or \u201cthe Company\u201d) (NASDAQ: CLLS) for violations of the securities laws. INVESTIGATION DETAILS: The investigation focuses on whether the Company issued false and\/or misleading statements and\/or failed to disclose information pertinent to investors. Cellectis announced on September 14, 2026, that it would prioritize in vivo gene editing therapies over CAR-T cell therapies. The Company also announced the discontinuation of development of certain CAR-T cell therapies. The Company\u2019s Chief Medical Officer stated, “Cellectis is not able finance [Eti-cel and Lasme-cel] … Continue reading \"CLLS Investors Have Opportunity to Join Cellectis S.A. Fraud Investigation with SBS Law\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/clls-investors-have-opportunity-to-join-cellectis-s-a-fraud-investigation-with-sbs-law\/","og_site_name":"Market Newsdesk","article_published_time":"2026-09-19T23:34:01+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20260919446999r1&sid=flmnd&distro=nx&lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/clls-investors-have-opportunity-to-join-cellectis-s-a-fraud-investigation-with-sbs-law\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/clls-investors-have-opportunity-to-join-cellectis-s-a-fraud-investigation-with-sbs-law\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"CLLS Investors Have Opportunity to Join Cellectis S.A. Fraud Investigation with SBS Law","datePublished":"2026-09-19T23:34:01+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/clls-investors-have-opportunity-to-join-cellectis-s-a-fraud-investigation-with-sbs-law\/"},"wordCount":357,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/clls-investors-have-opportunity-to-join-cellectis-s-a-fraud-investigation-with-sbs-law\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20260919446999r1&sid=flmnd&distro=nx&lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/clls-investors-have-opportunity-to-join-cellectis-s-a-fraud-investigation-with-sbs-law\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/clls-investors-have-opportunity-to-join-cellectis-s-a-fraud-investigation-with-sbs-law\/","name":"CLLS Investors Have Opportunity to Join Cellectis S.A. Fraud Investigation with SBS Law - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/clls-investors-have-opportunity-to-join-cellectis-s-a-fraud-investigation-with-sbs-law\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/clls-investors-have-opportunity-to-join-cellectis-s-a-fraud-investigation-with-sbs-law\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20260919446999r1&sid=flmnd&distro=nx&lang=en","datePublished":"2026-09-19T23:34:01+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/clls-investors-have-opportunity-to-join-cellectis-s-a-fraud-investigation-with-sbs-law\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/clls-investors-have-opportunity-to-join-cellectis-s-a-fraud-investigation-with-sbs-law\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/clls-investors-have-opportunity-to-join-cellectis-s-a-fraud-investigation-with-sbs-law\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20260919446999r1&sid=flmnd&distro=nx&lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20260919446999r1&sid=flmnd&distro=nx&lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/clls-investors-have-opportunity-to-join-cellectis-s-a-fraud-investigation-with-sbs-law\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"CLLS Investors Have Opportunity to Join Cellectis S.A. Fraud Investigation with SBS Law"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1004633","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=1004633"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1004633\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=1004633"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=1004633"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=1004633"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}